JP2016503399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503399A5 JP2016503399A5 JP2015539782A JP2015539782A JP2016503399A5 JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5 JP 2015539782 A JP2015539782 A JP 2015539782A JP 2015539782 A JP2015539782 A JP 2015539782A JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- cetuximab
- administered
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718430P | 2012-10-25 | 2012-10-25 | |
| US61/718,430 | 2012-10-25 | ||
| PCT/US2013/066564 WO2014066606A2 (en) | 2012-10-25 | 2013-10-24 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503399A JP2016503399A (ja) | 2016-02-04 |
| JP2016503399A5 true JP2016503399A5 (enExample) | 2016-12-08 |
Family
ID=50545472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539782A Pending JP2016503399A (ja) | 2012-10-25 | 2013-10-24 | 組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150273057A1 (enExample) |
| EP (1) | EP2911673A4 (enExample) |
| JP (1) | JP2016503399A (enExample) |
| KR (1) | KR20150070393A (enExample) |
| CN (1) | CN104812391A (enExample) |
| AU (1) | AU2013334599B2 (enExample) |
| BR (1) | BR112015009134A2 (enExample) |
| CA (1) | CA2889530A1 (enExample) |
| MX (1) | MX2015005307A (enExample) |
| RU (1) | RU2015119218A (enExample) |
| WO (1) | WO2014066606A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181243B2 (en) * | 2013-12-03 | 2015-11-10 | Hangzhou Pushai Pharmaceutical Technology Co. Ltd. | Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof |
| KR20160088884A (ko) * | 2013-12-12 | 2016-07-26 | 노파르티스 아게 | 암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물 |
| WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
| DK3110447T3 (da) * | 2014-09-16 | 2020-06-22 | Synermore Biologics Co Ltd | Anti-EGFR-antistof og anvendelser heraf |
| US20170027951A1 (en) * | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| WO2017180461A1 (en) * | 2016-04-15 | 2017-10-19 | Eli Lilly And Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
| FI3463345T3 (fi) * | 2016-06-03 | 2023-01-31 | Farmaseuttisia yhdistelmiä | |
| RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| EP4259147A4 (en) * | 2020-12-11 | 2024-10-23 | Erasca, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| DE602005004286T2 (de) * | 2004-06-11 | 2009-01-02 | Japan Tobacco Inc. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs |
| WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
| WO2009099634A2 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Picoplatin and amrubicin to treat lung cancer |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2470898A4 (en) * | 2009-08-24 | 2013-03-13 | Genentech Inc | DETERMINATION OF THE SENSITIVITY OF CELLS FOR B-RAF HEMMER TREATMENT BY DETECTION OF KRAS MUTATIONS AND RTK EXPRESSION MIRRORS |
| AU2010306653B2 (en) * | 2009-10-16 | 2013-10-24 | Novartis Ag | Combination |
| US10016440B2 (en) * | 2010-04-21 | 2018-07-10 | Ventirx Pharmaceuticals, Inc. | Methods of enhancing antibody-dependent cellular cytotoxicity |
| FR2968557A1 (fr) * | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| AU2012223639B2 (en) * | 2011-02-28 | 2015-03-19 | Sunshine Lake Pharma Co., Ltd. | Substituted quinoline compounds and methods of use |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| MX375442B (es) * | 2012-09-21 | 2025-03-06 | Intensity Therapeutics Inc | Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer. |
-
2013
- 2013-10-24 CA CA2889530A patent/CA2889530A1/en not_active Abandoned
- 2013-10-24 WO PCT/US2013/066564 patent/WO2014066606A2/en not_active Ceased
- 2013-10-24 RU RU2015119218A patent/RU2015119218A/ru not_active Application Discontinuation
- 2013-10-24 KR KR1020157013212A patent/KR20150070393A/ko not_active Ceased
- 2013-10-24 AU AU2013334599A patent/AU2013334599B2/en not_active Ceased
- 2013-10-24 EP EP13848440.7A patent/EP2911673A4/en not_active Withdrawn
- 2013-10-24 US US14/437,231 patent/US20150273057A1/en not_active Abandoned
- 2013-10-24 MX MX2015005307A patent/MX2015005307A/es unknown
- 2013-10-24 JP JP2015539782A patent/JP2016503399A/ja active Pending
- 2013-10-24 CN CN201380056222.9A patent/CN104812391A/zh active Pending
- 2013-10-24 BR BR112015009134A patent/BR112015009134A2/pt not_active IP Right Cessation